Evolus, Inc. (NASDAQ:EOLS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Evolus, Inc. (NASDAQ:EOLS) has been given a consensus rating of “Moderate Buy” by the six research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $16.00.

A number of equities analysts have recently commented on the stock. Stifel Nicolaus cut their target price on shares of Evolus from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, January 13th. BTIG Research reaffirmed a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Wednesday, March 4th. Mizuho set a $15.00 price target on Evolus in a report on Wednesday, February 4th. Wall Street Zen lowered Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd.

Insiders Place Their Bets

In other news, insider David Moatazedi sold 116,720 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $570,760.80. Following the completion of the transaction, the insider directly owned 618,369 shares in the company, valued at approximately $3,023,824.41. This represents a 15.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rui Avelar sold 29,996 shares of Evolus stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the sale, the insider directly owned 430,542 shares in the company, valued at $2,105,350.38. This trade represents a 6.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 163,504 shares of company stock worth $797,184. Corporate insiders own 5.90% of the company’s stock.

Institutional Trading of Evolus

A number of large investors have recently modified their holdings of EOLS. Nantahala Capital Management LLC raised its holdings in shares of Evolus by 1.6% during the fourth quarter. Nantahala Capital Management LLC now owns 5,820,649 shares of the company’s stock valued at $38,707,000 after buying an additional 93,792 shares during the last quarter. Caligan Partners LP grew its holdings in Evolus by 23.8% in the 3rd quarter. Caligan Partners LP now owns 4,138,943 shares of the company’s stock worth $25,413,000 after buying an additional 796,973 shares in the last quarter. Vanguard Group Inc. grew its holdings in Evolus by 3.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,428,943 shares of the company’s stock worth $21,054,000 after buying an additional 110,693 shares in the last quarter. Braidwell LP acquired a new stake in Evolus in the 4th quarter valued at approximately $20,650,000. Finally, Frazier Life Sciences Management L.P. acquired a new stake in Evolus in the 2nd quarter valued at approximately $22,431,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Price Performance

NASDAQ:EOLS traded down $0.14 during trading hours on Friday, reaching $4.04. 361,364 shares of the company were exchanged, compared to its average volume of 1,331,690. The firm has a market cap of $262.52 million, a price-to-earnings ratio of -5.01 and a beta of 1.02. The stock has a 50 day simple moving average of $4.72 and a 200 day simple moving average of $5.97. Evolus has a 52-week low of $4.04 and a 52-week high of $12.51.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analysts’ expectations of $89.58 million. On average, analysts predict that Evolus will post -0.61 EPS for the current fiscal year.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.